Establishing risk of human experimentation with drugs: lessons from TGN1412

Lancet

Volumn 368, Issue 9544, 2006, Pages 1387-1391

  Kenter, MJH ^a   Cohen, AF ^a,b  

^a Central Committee on Research Involving Human Subjects   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TGN 1412; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; HUMAN EXPERIMENT; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; VOLUNTEER;

EID: 33749648484     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69562-7     Document Type: Note

References (29)

1. Bresalier R., Sandler R., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
2. Council for International Organizations of Medical Sciences. Safety requirements for the first use of new drugs and diagnostic agents in man: a review of safety issues in early clinical trials of drugs (1983), Council for International Organizations of Medical Sciences, Geneva
3. Orme M., Harry J., Routledge P., and Hobson S. Healthy volunteer studies in Great Britain: the results of a survey into 12 months activity in this field. Br J Clin Pharmacol 27 (1989) 125-133
4. Zarafonetis C., Riley Jr. P., Willis III P., et al. Clinically significant adverse effects in a phase 1 testing program. Clin Pharmacol Ther 24 (1978) 127-132
5. Bouchie A. Gene-therapy death prompts suit. Nat Biotechnol 20 (2002) 647
6. Carmen I. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 3 (2001) 425-428
7. Steinbrook R. Protecting research subjects: the crisis at Johns Hopkins. N Engl J Med 346 (2002) 716-720
8. Schneider C., Kalinke U., and Lower J. TGN1412: a regulator's perspective. Nat Biotechnol 24 (2006) 493-496
9. Bhogal N., and Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Altern Lab Anim 34 (2006) 225-239
10. Wadman M. London's disastrous drug trial has serious side effects for research. Nature 440 (2006) 388-389
11. Jiang H., and Chess L. Regulation of immune responses by T cells. N Engl J Med 354 (2006) 1166-1176
12. Barr T., Carlring J., and Heath A. Co-stimulatory agonists as immunological adjuvants. Vaccine 24 (2006) 3399-3407
13. Evans E., Esnouf R., Manso-Sancho R., et al. Crystal structure of a soluble CD28-Fab complex. Nat Immunol 6 (2005) 271-279
14. Phan G., Yang J., Sherry R., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003) 8372-8377
15. Beck K., Blansfield J., Tran K., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24 (2006) 2283-2289
16. Blansfield J., Beck K., Tran K., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28 (2005) 593-598
17. Smith J., and Bluestone J. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs. Curr Opin Immunol 9 (1997) 648-654
18. Carpenter P., Pavlovic S., Tso J., et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 165 (2000) 6205-6213
19. Carpenter P., Tso J., Press O., Yu X., and Anasetti C. Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo. Transplant Proc 32 (2000) 1545-1546
20. Parexel. Parexel clinical trial protocol: a phase-I single-centre, double-blind, randomised, placebo controlled, single escalating-dose study to assess the safety, pharmacokinetics, pharmacodynamics and immunogenicity of TGN1412 administered intravenously to healthy volunteers (2006), Parexel International, London. Available at: http://www.circare.org/foia5/tgn1412protocol.pdf (accessed Aug 23, 2006)
21. TeGenero Immunotherapeutics. Investigator's brochure: TGN1412-humanized agonistic anti-CD28 monoclonal antibody, edn 1.1 2005-12-19 (2005), TeGenero AG, Würzburg. Available at: http://www.circare.org/foia5/tgn1412investigatorbrochure.pdf (accessed Aug 23, 2006)
22. Lühder F., Huang Y., Dennehy K., et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197 (2003) 955-966
23. Altschul S., Madden T., Schaffer A., et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25 (1997) 3389-3402
24. Legrand N., Cupedo T., van Lent A., et al. Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2-/-γc-/-mice. Blood 108 (2006) 238-245
25. Venuprasad K., Chattopadhyay S., and Saha B. CD28 signaling in neutrophil induces T-cell chemotactic factor(s) modulating T-cell response. Hum Immunol 64 (2003) 38-43
26. Venuprasad K., Parab P., Prasad D., et al. Immunobiology of CD28 expression on human neutrophils: I-CD28 regulates neutrophil migration by modulating CXCR-1 expression. Eur J Immunol 31 (2001) 1536-1543
27. Lewis C., McCarthy S., Lorenzen J., and McGee J. Differential effects of LPS, IFN-gamma and TNF alpha on the secretion of lysozyme by individual human mononuclear phagocytes: relationship to cell maturity. Immunology 69 (1990) 402-408
28. Medicines and Health Care Products Regulatory Agency. Pharmaco-toxicological (safety) assessment of TGN1412 (2005), Medicines and Health Care Products Regulatory Agency, London
29. Department of Health. Expert scientific group on phase one clinical trials: a consultation. http://www.dh.gov.uk/Consultations/LiveConsultations/LiveConsultationsAr ticle/fs/en?CONTENT_ID=4137501&chk=x%2BoJ/%2B (accessed Aug 23, 2006)